11 research outputs found
Performance evaluation of classification algorithms on diagnosis of breast cancer and skin disease
No full textHealth is so important for human beings. Thanks to the technological developments both in medicine and information technologies, the success percentages of both medical diagnosing and medical treatment systems are increasing day by day. Cancer is the most common causes of death in today’s world and is generally diagnosed at the last stages. Cancer has many types such as breast cancer, skin cancer, leukemia and etc. Diagnosis of cancer at early stages is very important for the success of medical treatments. The aim of this study was to evaluate the classification performances of some popular algorithms on the way to design an efficient computer aided breast and/or skin cancer diagnosing system to support the doctors and patients. For this purpose, same machine learning and deep learning algorithms were applied on immunotherapy dataset and breast cancer Coimbra dataset from UCI machine learning data repository. Feature selection by information gain and reliefF were applied on datasets before classification in order to increase the efficiency of classification processes. Support Vector Machines (SVM), Random Forest (RF), Recurrent Neural Network (RNN) and Convolutional Neural Network (CNN) algorithms were used for classification experiments. Accuracy values are used for performance metric. According to these results, RNN has shown the best performance among the others with 92% on both datasets. This shows that deep learning algorithms especially RNN has great potential to diagnose the cancer from dataset with high success ratios. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd 2021
Classification Performance Evaluation on Diagnosis of Breast Cancer
No full textCancer, which has many different types such as breast, pleural, and leukemia, is one of the common health problems of today. Most of them cause pain and treatment processes are so challenging. Medical authorities report that the diagnosis of cancer at early stages has a positive effect on medical treatments' success. On the way to design a computer-aided cancer diagnosis system about breast cancer to support the decisions of doctors about medical treatments, classification performances of six classifiers are investigated in this study. For this purpose, classifier models have been created with machine learning algorithms such as Support Vector Machine (SVM), Naïve Bayes (NB) and Random Forest (RF); and deep learning algorithms such as Recurrent Neural Network (RNN), Gated Recurrent Unit (GRU), and Long Short-Term Memory Network (LSTM). Two different open-source breast cancer datasets were used namely Wisconsin and Coimbra on experiments. Accuracy (Acc), Sensitivity (Sens), Precision (Pre), F-measure (F) were used as performance criteria. As a result of the tests, Acc values between 85% and 98% were obtained in the Coimbra breast cancer dataset; while Acc values were obtained between 92% and 97% in Wisconsin. According to the results obtained, it is seen that deep learning algorithms (RNN, GRU, and LSTM) are more successful than machine learning algorithms (SVM NB and RF). Among the deep learning algorithms, LSTM is more successful. © 2021, The Author(s), under exclusive license to Springer Nature Switzerland AG
A Hybrid Classification Example in the Diagnosis of Skin Disease with Cryotherapy and Immunotherapy Treatment
No full text2nd International Symposium on Multidisciplinary Studies and Innovative Technologies (ISMSIT) -- OCT 19-21, 2018 -- Kizilcahamam, TURKEYUncontrolled tumors in the human body are called cancer. Unbalanced diet, alcohol and cigarette use, food additives and a variety of viruses can cause people have cancer. Cancer-causing tumors can be good or malignant. This study will measure the responses to treatments for skin disease caused by human papilloma virus (HPV), also called wart virus, which is directly related to cancer. This virus is an infectious virus that can infect another person by contact. There are multiple types of HPV virus and although it is usually benign, it can cause cancers such as cervical cancer, skin cancer. Apart from cancer, warts caused by HPV virus are generally seen on hands, feet, face and genital areas. As the skin grows and sagging progresses, it causes cancer at advanced levels. As a treatment method; drug use, surgical removal and HPV virus vaccination are used. These methods may require various surgical interventions. It can also cause a variety of reactions to allergic patients or it can cause a slight dependence on drug use. In addition to these methods, cryotherapy (ice treatment) and immunotherapy methods are used which are developed to obtain faster results and less costly than drugs and surgical interventions. In this study, it was estimated that 180 patients with warts on hands and feet who applied to the dermatology clinic of Ghaem Hospital in Iran were divided into two groups and responded to the treatment with two separate data sets obtained by applying cryotherapy in the other half and immunotherapy treatment in the other half. These data sets are located in the UCI data set. Navie Bayes, C4.5 decision tree, logistic regression, k-nearest neighbor classifier models have been developed for estimation work. In addition, the classification of the features included in the immunotherapy and cryotherapy data sets were tested by applying the feature selection process. The performance of the data sets after attribute selection and the performance of the raw data sets in the classification models are compared. 5 and 10 times cross validation is used to compare the performance of these models. The study also gave the best performance in all the performance criteria of the 4 different classifiers in the two datasets that are used as common models with the C4.5 Decision Tree. In addition, it is clearly seen that the attribute selection process has increased the performance criteria of all models.IEEE Turkey Sect,Karabuk Univ,Kutahya Dumlupinar Uni
Is intralipid fat emulsion a promising therapeutic strategy on neurotoxicity induced by malathion in rats?
No full textAIM: Malathion is one of the most widely used organophosphate pesticides and herbicides. It has given rise to major clinical problems by its poisoning in all over the world. Malathion also a highly lipophilic agent, and tends to accumulate within lipid-rich tissue like a brain in the body, causing toxicity. Therefore, the study was aimed to investigate if there is a possible beneficial effect of using intralipid fat emulsion (IFE) on the neurotoxicity, and to detect it time-dependently at the beginning, 6th and 12th hours of M intoxication. MATERIALS AND METHODS: Forty-eight rats were randomly divided into six groups including: control (C), Lipid (L) group (18.6 mL/kg oral IFE), Malathion (M) group (10 mg/kg oral M), M0L group (IFE treated after immediate from M), M6L group (IFE treated after 6 hours from M), M12L group (IFE treated after 12 hours from M). RESULTS: M group in comparison with all others group, there was an increase in the total oxidant status (TOS) level. M group in comparison with C, L, M0L groups, it was seen significantly decrease in the total antioxidant capacity (TAC) level. Interestingly, M group in comparison with M6L and M12L groups, there was no significant difference among these groups in terms of the TAC levels. Although there was no significant difference among C, L and M0L groups in terms of both TAC and TOS levels, but was significant difference C, L groups in comparison with M6L, M12L groups in terms of TAC levels. C group in comparison with L, M0L, M6L, M12L groups in terms of TOS levels, there was no significant difference. These findings have indicated that IFE seriously reduced TOS levels in all the groups depending on time. Also, M0L group in comparison with M6L and M12L groups, there was significantly increase of the TAC levels. There was no statistically significant difference between M6L and M12L groups. These biochemical results were confirmed with immunohistochemical results. CONCLUSIONS:The study has had some certain evidence that IFE is a promising safe therapy for acutely intoxicated cases by organophosphate. It is much more effective if used at the beginning of organophosphate poisoning. As such, there is no need to avoid using IFE in clinical practice
Is intralipid fat emulsion a promising therapeutic strategy on neurotoxicity induced by malathion in rats?
No full textAIM: Malathion is one of the most widely used organophosphate pesticides and herbicides. It has given rise to major clinical problems by its poisoning in all over the world. Malathion also a highly lipophilic agent, and tends to accumulate within lipid-rich tissue like a brain in the body, causing toxicity. Therefore, the study was aimed to investigate if there is a possible beneficial effect of using intralipid fat emulsion (IFE) on the neurotoxicity, and to detect it time-dependently at the beginning, 6th and 12th hours of M intoxication. MATERIALS AND METHODS: Forty-eight rats were randomly divided into six groups including: control (C), Lipid (L) group (18.6 mL/kg oral IFE), Malathion (M) group (10 mg/kg oral M), M0L group (IFE treated after immediate from M), M6L group (IFE treated after 6 hours from M), M12L group (IFE treated after 12 hours from M). RESULTS: M group in comparison with all others group, there was an increase in the total oxidant status (TOS) level. M group in comparison with C, L, M0L groups, it was seen significantly decrease in the total antioxidant capacity (TAC) level. Interestingly, M group in comparison with M6L and M12L groups, there was no significant difference among these groups in terms of the TAC levels. Although there was no significant difference among C, L and M0L groups in terms of both TAC and TOS levels, but was significant difference C, L groups in comparison with M6L, M12L groups in terms of TAC levels. C group in comparison with L, M0L, M6L, M12L groups in terms of TOS levels, there was no significant difference. These findings have indicated that IFE seriously reduced TOS levels in all the groups depending on time. Also, M0L group in comparison with M6L and M12L groups, there was significantly increase of the TAC levels. There was no statistically significant difference between M6L and M12L groups. These biochemical results were confirmed with immunohistochemical results. CONCLUSIONS: The study has had some certain evidence that IFE is a promising safe therapy for acutely intoxicated cases by organophosphate. It is much more effective if used at the beginning of organophosphate poisoning. As such, there is no need to avoid using IFE in clinical practice
A hybrid classification example in the diagnosis of skin disease with cryotherapy and immunotherapy treatmec
No full textBaşarslan, Muhammet Sinan (Dogus Author) -- Conference full title: 2nd International Symposium on Multidisciplinary Studies and Innovative Technologies (ISMSIT); IEEE; Ankara; Turkey; 19 October 2018 through 21 October 2018.Uncontrolled tumors in the human body are called cancer. Unbalanced diet, alcohol and cigarette use, food additives and a variety of viruses can cause people have cancer. Cancercausing tumors can be good or malignant. This study will measure the responses to treatments for skin disease caused by human papilloma virus (HPV), also called wart virus, which is directly related to cancer. This virus is an infectious virus that can infect another person by contact. There are multiple types of HPV virus and although it is usually benign, it can cause cancers such as cervical cancer, skin cancer. Apart from cancer, warts caused by HPV virus are generally seen on hands, feet, face and genital areas. As the skin grows and sagging progresses, it causes cancer at advanced levels. As a treatment method; drug use, surgical removal and HPV virus vaccination are used. These methods may require various surgical interventions. It can also cause a variety of reactions to allergic patients or it can cause a slight dependence on drug use. In addition to these methods, cryotherapy (ice treatment) and immunotherapy methods are used which are developed to obtain faster results and less costly than drugs and surgical interventions. In this study, it was estimated that 180 patients with warts on hands and feet who applied to the dermatology clinic of Ghaem Hospital in Iran were divided into two groups and responded to the treatment with two separate data sets obtained by applying cryotherapy in the other half and immunotherapy treatment in the other half. These data sets are located in the UCI data set. Navie Bayes, C4.5 decision tree, logistic regression, k- nearest neighbor classifier models have been developed for estimation work. In addition, the classification of the features included in the immunotherapy and cryotherapy data sets were tested by applying the feature selection process. The performance of the data sets after attribute selection and the performance of the raw data sets in the classification models are compared. 5 and 10 times cross validation is used to compare the performance of these models. The study also gave the best performance in all the performance criteria of the 4 different classifiers in the two datasets that are used as common models with the C4.5 Decision Tree. In addition, it is clearly seen that the attribute selection process has increased the performance criteria of all models.İnsan vücudunda kontrol dışı gelişen tümörlere kanser denir. Dengesiz beslenme, alkol ve sigara kullanımı, yemeklerdeki katkı maddeleri ve çeşitli virüsler aracılığı ile insanlar kanser hastası olabilmektedirler. Kansere sebep olan tümörler iyi veya kötü huylu olabilir. Bu çalışma da kanser ile direk ilişkisi olan Human papilloma virüsü (hpv) diğer adıyla siğil virüsünün sebep olduğu cilt hastalığına yönelik uygulanan tedavilere verilen tepkiler ölçülecektir. Bu virüs bulaşıcı bir virüs olup insanların ciltlerinin temas etmesi sonucu bir insandan diğerine bulaşır. HPV virüsünün birden çok türü vardır ve genelde iyi huylu olmasına rağmen rahim ağzı kanseri, cilt kanseri gibi kanserlere sebep olabilmektedir. Kanserin dışında HPV virüsünün sebep olduğu siğiller el ve ayaklarda, yüz ve genital bölgelerde görülür. Cilt büyüme ve sarkmasının ilerlemesi ile beraber ileri derecelerde kansere sebep olur. Tedavi yöntemi olarak; ilaç kullanımı, ameliyat ile alınma ve HPV virüs aşısı gibi yöntemler kullanılır. Bu yöntemler çeşitli cerrahi müdahaleler gerektirebilir. Ayrıca ilaç kullanımı ile ilaca bağımlılığa sebep olmasıyla beraber alerjik hastalarda ilaca farklı tepkiler de verilebilir. Bu yöntemlerin dışında daha hızlı ilaç ve cerrahi müdahaleye göre daha az masraflı ve hızlı sonuç almak için geliştirilen kroyoterapi (Buz tedavisi) ve immunoterapi yöntemleri kullanılır. Bu çalışmada İran'daki Ghaem Hastanesinin dermatoloji kliniğine başvuran el ve ayaklarında siğil olan 180 hasta ikiye ayrılarak yarısında kroyoterapi, diğer yarısında immunoterapi tedavisi uygulanarak elde edilen iki ayrı veri seti ile tedaviye cevap vermeleri tahmin edilmiştir. Bu veri setleri UCI veri setinde yer almaktadır. Tahmin çalışması için Navie Bayes, C4.5 karar ağacı, logistik regresyon, k en yakın komşu algoritmaları ile sınıflayıcı modeller oluşturulmuştur. Ayrıca immunoterapi ve kroyoterapi veri setlerinde yer alan özniteliklerin sınıflandırma da etkisi öznitelik seçme işlemi uygulanarak test edilmiştir. Öznitelik seçme işlemi sonrası oluşan veri setleri ile ham veri setlerinin sınıflandırma modellerindeki başarısı karşılaştırılmıştır. Bu modellerin performanslarının karşılaştırılması için 5 ve 10 kat çapraz geçerleme yöntemi kullanılmıştır. Çalışma da ortak olarak kullanılan iki veri setinde de 4 ayrı sınıflayıcı modellerinin tüm performans kriterlerinde diğer modellere göre en iyi performansı C4.5 Karar ağacı ile oluşturulan modeller vermiştir. Ayrıca öznitelik seçme işlemi uygulanan veri setlerinin tüm performans kriterlerinde artışı görülmüştür
Effects of erdosteine on hemostasis
No full text Aim: In this study, the effects of erdosteine (ED) on the platelet function and coagulation were investigated in adult rats. Materials and Method: Twenty-eight male Wistar albino rats were divided into four groups. The control rats in group I ( n = 7) were given only 0.5 cc of normal saline daily through oral gavage. Group II ( n = 7) rats were administered 3 mg/kg ED through oral gavage for 3 days; while group III ( n = 7) rats were given 10 mg/kg ED through oral gavage for 3 days; and group IV ( n = 7) rats were administered 30 mg/kg ED through oral gavage for 3 days. Prothrombin time (PT), activated prothromboplastin time (aPTT), international normalized ratio (INR), coagulation factors and complete blood counts were measured from the blood drawn. Results: There were a lot of differences between ED groups and control group, and among ED groups. The found differences were level of PT, aPTT, INR, coagulation factors, and number of platelets. Discussion: We consider that ED which is used as a mucolytic agent in child clinics may affect hemostasis and coagulation in a dose-dependent manner. ED should be used carefully by the patients with coagulation disorders, since there is no information available in the package insert and literature screening regarding the effect of ED. </jats:p
TSCBAS: a novel correlation based attribute selection method and application on telecommunications churn analysis
No full textBaşarslan, Muhammet Sinan (Dogus Author) -- Conference full title: 2018 International Conference on Artificial Intelligence and Data Processing (IDAP); IEEE; Malatya; Turkey; 28 September 2018 through 30 September 2018.Attribute selection has a significant effect on the performance of the machine learning studies by selecting the attributes having significant effect on result, reducing the number of attributes, and reducing the calculation cost. In this study, a new attribute selection method which is a combination of the Rcorrelation coefficient-based attribute selection (RCBAS) and the ρ-correlation coefficient-based attribute selection (ρCBAS) called the Two-Stage Correlation-Based Attribute Selection (TSCBAS) is proposed to select significant attributes. The proposed attribute selection method has been applied to customer churn prediction on a telecommunications dataset for performance evaluation. The dataset used in the study includes real customer call records details for the years 2013 and 2014 obtained from a major telecommunications company in Turkey. Apart from the proposed attribute selection method, four different methods named Rcorrelation coefficient-based attribute selection, ρ-correlation coefficient-based attribute selection, ReliefF, and Gain Ratio have been used for creating five datasets. After that, four classifier algorithms including Random Forest, C4.5 Decision Tree, Naive Bayes and AdaBoost.M1 have been applied. The obtained results have been compared according to the performance metrics comprising Accuracy (ACC), Sensitivity (TPR), Specificity (SPC), F-measure (F), AUC (area under the ROC curve), and run-time. The results of the comparisons show that the proposed attribute selection algorithm outperforms the state of the art methods on customer churn prediction
Thymoquinone: Fifty years of success in the battle against cancer models
No full textThymoquinone (TQ), the main active constituent of black seed essential oil, exhibits promising effects against inflammatory diseases and cancer. TQ, modulates signaling pathways that are key to cancer progression, and enhances the anticancer potential of clinical drugs while reducing their toxic side effects. Considering that TQ was isolated 50 years ago, this review focuses on TQ's chemical and pharmacological properties and the latest advances in TQ analog design and nanoformulation. We discuss our current state of knowledge of TQ's adjuvant potential and in vivo antitumor activity and highlight its ability to modulate the hallmarks of cancer. © 2013 Elsevier Ltd. All rights reserved.Abusnina A, 2011, CELL SIGNAL, V23, P152, DOI 10.1016-j.cellsig.2010.08.015; Akhondian J, 2011, EPILEPSY RES, V93, P39, DOI 10.1016-j.eplepsyres.2010.10.010; Al-Ali Amein, 2008, J Ayub Med Coll Abbottabad, V20, P25; Alam S, 2012, INT J NANOMED, V7, P5705, DOI 10.2147-IJN.S35329; Al-Amri A. M., 2009, Shiraz E Medical Journal, V10, P107; Alenzi FQ, 2010, BRIT J BIOMED SCI, V67, P20; Alhosin M, 2012, INVEST NEW DRUG, V30, P1813, DOI 10.1007-s10637-011-9734-1; Alhosin M, 2010, BIOCHEM PHARMACOL, V79, P1251, DOI 10.1016-j.bcp.2009.12.015; Al-Johar D, 2008, PHYTOTHER RES, V22, P1311, DOI 10.1002-ptr.2487; Al-Shabanah OA, 1998, J EXP CLIN CANC RES, V17, P193; Arafa ESA, 2011, MUTAT RES-FUND MOL M, V706, P28, DOI 10.1016-j.mrfmmm.2010.10.007; Badary OA, 2001, CANCER DETECT PREV, V25, P362; Badary OA, 1999, J ETHNOPHARMACOL, V67, P135, DOI 10.1016-S0378-8741(98)00242-6; Badary OA, 1999, EUR J CANCER PREV, V8, P435, DOI 10.1097-00008469-199910000-00009; Badary OA, 2000, TOXICOLOGY, V143, P219, DOI 10.1016-S0300-483X(99)00179-1; Badr G, 2011, PLOS ONE, V6, DOI 10.1371-journal.pone.0023741; Banerjee S, 2010, NUTR CANCER, V62, P938, DOI 10.1080-01635581.2010.509832; Banerjee S, 2010, PHARM RES-DORDR, V27, P1146, DOI 10.1007-s11095-010-0145-3; Banerjee S, 2009, CANCER RES, V69, P5575, DOI 10.1158-0008-5472.CAN-08-4235; Basarslan F, 2012, HUM EXP TOXICOL, V31, P726, DOI 10.1177-0960327111433185; Brewer J, 2006, BIOMED SCI INSTRUM, V42, P37; Chehl N, 2009, HPB, V11, P373, DOI 10.1111-j.1477-2574.2009.00059.x; CREMER D, 1987, J MED CHEM, V30, P1678, DOI 10.1021-jm00392a027; Daba MH, 1998, TOXICOL LETT, V95, P23, DOI 10.1016-S0378-4274(98)00012-5; Das S, 2012, PLOS ONE, V7, DOI 10.1371-journal.pone.0046641; Dergarabetian Eileen Manasse, 2013, Front Biosci (Elite Ed), V5, P706; Effenberger K, 2010, CHEM BIODIVERS, V7, P129, DOI 10.1002-cbdv.200900328; Effenberger-Neidnicht K, 2011, CHEMBIOCHEM, V12, P1237, DOI 10.1002-cbic.201000762; El-Dakhakhny M., 1963, PLANTA MED, V11, P465; El-Dakhakhny M, 2002, J ETHNOPHARMACOL, V81, P161, DOI 10.1016-S0378-8741(02)00051-X; El Gazzar MA, 2007, BBA-GEN SUBJECTS, V1770, P556, DOI 10.1016-j.bbagen.2007.01.002; El-Mahdy MA, 2005, INT J CANCER, V117, P409, DOI 10.1002-ijc.21205; El Mezayen R, 2006, IMMUNOL LETT, V106, P72, DOI 10.1016-j.imlet.2006.04.012; El-Najjar N, 2010, APOPTOSIS, V15, P183, DOI 10.1007-s10495-009-0421-z; El-Najjar Nahed, 2011, J Chem Biol, V4, P97, DOI 10.1007-s12154-010-0052-4; Farah Nourelhoda, 2005, V41, P211; Fouda AMM, 2008, BASIC CLIN PHARMACOL, V103, P109, DOI 10.1111-j.1742-7843.2008.00260.x; Gali-Muhtasib H, 2008, J CELL MOL MED, V12, P330, DOI 10.1111-j.1582-4934.2007.00095.x; Gali-Muhtasib H, 2006, INT J BIOCHEM CELL B, V38, P1249, DOI 10.1016-j.biocel.2005.10.009; Gali-Muhtasib H, 2008, CANCER RES, V68, P5609, DOI 10.1158-0008-5472.CAN-08-0884; Gali-Muhtasib H, 2004, INT J ONCOL, V25, P857; Gali-Muhtasib HU, 2004, ANTI-CANCER DRUG, V15, P389, DOI 10.1097-01.cad.0000125054.43188.56; Ganea GM, 2010, NANOTECHNOLOGY, V21, DOI 10.1088-0957-4484-21-28-285104; Gohari AR, 2012, SCI WORLD J, DOI 10.1100-2012-203861; Gokce A, 2011, HUM EXP TOXICOL, V30, P897, DOI 10.1177-0960327110382564; Grosso C, 2010, J SEP SCI, V33, P2211, DOI 10.1002-jssc.201000192; Gupta V.K., 2010, INT J RES PHARM SCI, V1, P163; Gurung R.L., 2010, PLOS ONE, V5; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016-j.cell.2011.02.013; Harzallah HJ, 2012, OXID MED CELL LONGEV, DOI 10.1155-2012-854065; Hussain AR, 2011, FREE RADICAL BIO MED, V50, P978, DOI 10.1016-j.freeradbiomed.2010.12.034; Hussain J, 2010, NAT PROD COMMUN, V5, P1785; Ivankovic S., 2006, Experimental Oncology, V28, P220; Jafri SH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186-1756-9966-29-87; Kanter M, 2005, WORLD J GASTROENTERO, V11, P6662; Kanter M, 2008, NEUROCHEM RES, V33, P579, DOI 10.1007-s11064-007-9481-z; Kanter M, 2011, TOXICOL IND HEALTH, V27, P387, DOI 10.1177-0748233710387630; Kaseb AO, 2007, CANCER RES, V67, P7782, DOI 10.1158-0008-5472.CAN-07-1483; Koka PS, 2010, EXP BIOL MED, V235, P751, DOI 10.1258-ebm.2010.009369; Kolli-Bouhafs K, 2012, INVEST NEW DRUG, V30, P2121, DOI 10.1007-s10637-011-9777-3; Lei XF, 2012, DIGEST DIS SCI, V57, P2296, DOI 10.1007-s10620-012-2156-x; Li F, 2010, BRIT J PHARMACOL, V161, P541, DOI 10.1111-j.1476-5381.2010.00874.x; Lukas B, 2009, J AGR FOOD CHEM, V57, P1362, DOI 10.1021-jf802963h; Mansour MA, 2000, LIFE SCI, V66, P2583, DOI 10.1016-S0024-3205(00)00592-0; Manter DK, 2007, J CHEM ECOL, V33, P2133, DOI 10.1007-s10886-007-9368-0; Martin TM, 2006, BIOMED SCI INSTRUM, V42, P332; Mu Hai-qi, 2012, Zhonghua Yi Xue Za Zhi, V92, P392; Nagi MN, 2011, J BIOCHEM MOL TOXIC, V25, P135, DOI 10.1002-jbt.20369; Nagi MN, 2000, PHARMACOL RES, V41, P283, DOI 10.1006-phrs.1999.0585; Nagi MN, 2010, FOOD CHEM TOXICOL, V48, P2361, DOI 10.1016-j.fct.2010.05.072; Ng WK, 2011, TOXICOL IN VITRO, V25, P1392, DOI 10.1016-j.tiv.2011.04.030; Nili-Ahmadabadi A, 2011, DARU, V19, P282; Norwood AA, 2006, BIOMED SCI INSTRUM, V42, P350; Odeh F, 2012, DRUG DELIV, V19, P371, DOI 10.3109-10717544.2012.727500; Paramasivam A, 2012, TOXICOL LETT, V213, P151, DOI 10.1016-j.toxlet.2012.06.011; Pathan SA, 2011, BIOMED CHROMATOGR, V25, P613, DOI 10.1002-bmc.1492; Ravindran J, 2010, BIOCHEM PHARMACOL, V79, P1640, DOI 10.1016-j.bcp.2010.01.023; Reindl WG, 2008, CHEM BIOL, V15, P459, DOI 10.1016-j.chembiol.2008.03.013; Richards LR, 2007, BIOMED SCI INSTRUM, V43, P242; Roepke M, 2007, CANCER BIOL THER, V6, P160; Rooney S, 2005, ANTICANCER RES, V25, P4255; Ross Richards L, 2009, BIOMED SCI INSTRUM, V45, P268; Salem ML, 2005, INT IMMUNOPHARMACOL, V5, P1749, DOI 10.1016-j.intimp.2005.06.008; Sayed-Ahmed MM, 2007, CLIN EXP PHARMACOL P, V34, P399, DOI 10.1111-j.1440-1681.2007.04560.x; Sethi G, 2008, MOL CANCER RES, V6, P1059, DOI 10.1158-1541-7786.MCR-07-2088; Shah M, 2010, INT J PHARMACEUT, V400, P165, DOI 10.1016-j.ijpharm.2010.08.008; Shah M, 2011, J NANOSCI NANOTECHNO, V11, P5702, DOI 10.1166-jnn.2011.4493; Singh A, 2013, COLLOID SURFACE B, V102, P822, DOI 10.1016-j.colsurfb.2012.08.038; Suddek GM, 2013, INFLAMMOPHARMACOLOGY, V21, P427, DOI 10.1007-s10787-012-0160-6; Sutton KM, 2012, BIOCHEM BIOPH RES CO, V426, P421, DOI 10.1016-j.bbrc.2012.08.111; Tan M, 2006, BIOMED SCI INSTRUM, V42, P363; Torres MP, 2010, MOL CANCER THER, V9, P1419, DOI 10.1158-1535-7163.MCT-10-0075; TRANG NTD, 1993, PLANTA MED, V59, P99, DOI 10.1055-s-2006-959619; Ulu R, 2012, FOOD CHEM TOXICOL, V50, P1675, DOI 10.1016-j.fct.2012.02.082; Velho-Pereira R, 2011, CELL BIOL INT, V35, P1025, DOI 10.1042-CBI20100701; Wang Yong-Mei, 2011, Zhonghua Yi Xue Za Zhi, V91, P3111; Wilson-Simpson F, 2007, BIOMED SCI INSTRUM, V43, P378; Woo CC, 2011, BIOCHEM PHARMACOL, V82, P464, DOI 10.1016-j.bcp.2011.05.030; Woo CC, 2012, BIOCHEM PHARMACOL, V83, P443, DOI 10.1016-j.bcp.2011.09.029; Worthen DR, 1998, ANTICANCER RES, V18, P1527; Wu Zhi-hao, 2011, Yaoxue Xuebao, V46, P910; Yi TF, 2008, MOL CANCER THER, V7, P1789, DOI 10.1158-1535-7163.MCT-08-0124; Yin Z, 2013, ACS CHEM BIOL, V8, P303, DOI 10.1021-cb3004379; Yuan JP, 2011, AM J PATHOL, V179, P2091, DOI 10.1016-j.ajpath.2011.06.031; Zafeer MF, 2012, J BIOCHEM MOL TOXIC, V26, P199, DOI 10.1002-jbt.2140268
N-Acetylcysteine prevents doxorubucine-induced cardiotoxicity in rats
No full textThis study is designed to observe the effects of N-acetylcysteine (NAC) on doxorubucine-induced cardiac toxicity in rats both histologically and biochemically. Totally 32 rats divided equally into four groups were studied. The first group received only 200 mg/kg NAC intraperitoneal (i.p.) once every 24 h for 5 days (group 1); the second group received 20 mg/kg doxorubucine (DOX) i.p. single dose plus NAC 200 mg/kg i.p. once every 24 h for 5 days (group 2); the third group received DOX 20 mg/kg DOX i.p. single dose (group 3) and the fourth group, which is also the control group, received saline (group 4). Following 24 h of the final dose, blood samples were drawn from a portal vein and heart tissue were obtained. Tissue thiobarbituric acid reactive substance (TBARS) and nitric oxide (NO) levels were highest in the DOX group. In the DOX-treated rats, serum TBARS, NO, aspartate transaminase, lactate dehydrogenase and creatine kinase levels were highest when compared with other groups. Except for serum superoxide dismutase levels, all other parameters differed significantly between the DOX plus NAC group and the DOX group. In the DOX plus NAC group, general architecture was preserved better than the DOX group and myofibril loss was minimal compared with the DOX group. NAC demonstrated, both biochemically and histologically, to be effective in the prevention of DOX-induced cardiotoxicity in rat models. Evaluation of NAC's effect on DOX toxicity warrants further clinical trials on cancer patients
